LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
57 hedge funds and large institutions have $73.2M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 11 closing their positions.
5% more capital invested
Capital invested by funds: $69.8M → $73.2M (+$3.45M)
10% less funds holding
Funds holding: 63 → 57 (-6)
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
75% less call options, than puts
Call options by funds: $14K | Put options by funds: $57K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.54M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.41M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$440K |
| 4 |
SC
Samlyn Capital
New York
|
+$236K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$811K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$416K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$340K |
| 4 |
JP Morgan Chase
New York
|
-$254K |
| 5 |
Renaissance Technologies
New York
|
-$217K |
LOGC Hedge Fund Activity: Q3 2021 in Review
57 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2021, worth a combined $73.2M — up 4.9% from $69.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LOGC and 5 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 10 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $1.54M. The largest seller was Fidelity Investments, cutting an estimated $811K.
- 57 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2021, down from 63 in Q2 2021.
- Funds reported $73.2M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2021, up 4.9% quarter-over-quarter.
- 5 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -6 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2021 was Eversept Partners, an estimated $1.54M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2021 was Fidelity Investments, an estimated $811K sold.
Based on aggregated 13F filings for Q3 2021.